Trials / Sponsors / Seagen, a wholly owned subsidiary of Pfizer
Seagen, a wholly owned subsidiary of Pfizer
Industry · 30 registered clinical trials — 7 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma | Phase 1 | 2024-08-21 |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma | Phase 1 | 2024-08-02 |
| Active Not Recruiting | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse | Phase 1 | 2024-05-28 |
| Recruiting | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms | Phase 2 | 2024-05-20 |
| Terminated | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral | Phase 1 | 2024-02-29 |
| Active Not Recruiting | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Phase 3 | 2024-02-21 |
| Recruiting | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms | Phase 1 | 2023-11-20 |
| Active Not Recruiting | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | 2023-11-14 |
| Active Not Recruiting | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | 2023-11-14 |
| Active Not Recruiting | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Urothelial Carcinoma | Phase 3 | 2023-09-22 |
| Completed | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study Urothelial Carcinoma | — | 2023-06-29 |
| Active Not Recruiting | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms | Phase 1 | 2023-01-03 |
| Recruiting | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma | Phase 1 | 2022-10-25 |
| Recruiting | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metas Colorectal Neoplasms | Phase 3 | 2022-10-24 |
| Recruiting | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Urothelial Carcinoma | Phase 2 | 2022-05-03 |
| Active Not Recruiting | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer HER2 Positive Breast Cancer | Phase 3 | 2022-03-07 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms | Phase 1 | 2022-01-12 |
| Completed | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Cervical Cancer | Phase 3 | 2021-02-22 |
| Completed | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | 2021-01-26 |
| Active Not Recruiting | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms | Phase 2 | 2021-01-11 |
| Completed | A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer HER2 Positive Breast Cancer | Phase 2 | 2020-12-01 |
| Completed | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Peripheral T-cell Lymphoma | Phase 2 | 2020-11-12 |
| Active Not Recruiting | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma | Phase 2 | 2020-09-15 |
| Active Not Recruiting | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Diffuse Large B-cell Lymphoma | Phase 3 | 2020-08-20 |
| Recruiting | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | 2020-08-07 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms | Phase 1 | 2020-06-08 |
| Active Not Recruiting | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advan HER2-positive Breast Cancer | Phase 3 | 2019-10-02 |
| Terminated | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects Wit Cervical Cancer | Phase 1 / Phase 2 | 2019-02-27 |
| Active Not Recruiting | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer | Phase 2 | 2018-06-25 |
| Approved For Marketing | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Tre HER2-positive Breast Cancer | — | — |